Skip to content
Services in Health Economics logoogo
  • Home
  • What We Do
    • Health Economic Modelling
    • Data Collection and Analysis
  • Publications
  • Clients
  • Meet Our Team
  • Get in touch

Home

Services in Health Economics

What are we good at?

Recent publications

Comparison of Emapalumab with Conventional Treatment in Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Consistent Results Obtained in an Unadjusted and an Adjusted Analysis
Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective
The combined impact of dependency on caregivers, disability and coping strategy on quality of life after ischemic stroke
The Relationship between home-time, quality of life and costs after ischemic stroke. The impact of the need for mobility aids, home and car modifications on home-time
Hospital financing of ischaemic stroke: determinants of funding and usefulness of DRG subcategories based on Severity of Illness
What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients’ Quality of Life?
Modified Rankin scale as a determinant of direct medical costs after stroke
The impact of cancer-associated thrombosis and treatment related bleedings on patients’ quality of life
Analysis of primary and secondary APR-DRG codes of an ischemic stroke admission
Utilities for treatment-related adverse events in type 2 diabetes
Investigating the relationship between Severity of Illness and the modified Rankin Scale in ischemic stroke patients with response mapping
Analysis of in-hospital resource use after an ischemic stroke
Quality of life of patients experiencing cancer-associated thrombosis
Health state utilities in non-small cell lung cancer: An international study
Place of residence and employment status after stroke
Quality of Life Decrements after Stroke
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales
Investigating Incoherence Gives Insight: the case of anti-platelet therapy for stroke prevention
Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment
Cost of hospitalization for cerebrovascular disorders in Belgium
Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences
Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany
Eliciting health state utilities from the general public for severe chronic pain
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer
Cost-effectiveness of warfarin: Trial versus ‘real-life’ stroke prevention in atrial fibrillation
Preferences and utilities for the symptoms of moderate to severe allergic asthma.
The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden
Health state utilities for metastatic breast cancer
Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma
The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer
Continuous retrograde blood cardioplegia is associated with lower hospital mortality after heart valve surgery
Create a website or blog at WordPress.com
  • Follow Following
    • she-consulting.be
    • Already have a WordPress.com account? Log in now.
    • she-consulting.be
    • Customize
    • Follow Following
    • Sign up
    • Log in
    • Copy shortlink
    • Report this content
    • View post in Reader
    • Manage subscriptions
    • Collapse this bar
 

Loading Comments...